Mark O’Neill

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Steven E. Kahn, Steven M. Haffner, Mark Heise et al. · New England Journal of Medicine · 2006 · 2.9K citations

Medicine, Endocrinology, Pharmacotherapy +13

Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe

Bernard Zinman, Steven E. Kahn, Steven M. Haffner et al. · Diabetes · 2004 · 202 citations · Full text

Medicine, Endocrinology, Immunology +17

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Steven E. Kahn, Bernard Zinman, Steven M. Haffner et al. · Diabetes · 2006 · 189 citations · Full text

Veterinary Medicine, Chronic Disease Prevention, Diabetology +16

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Julio Rosenstock, B. J. Goldstein, A Vinik et al. · Diabetes Obesity and Metabolism · 2005 · 61 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial

Claire Baker, Suman Wason, Phillip Banks et al. · Diabetes Obesity and Metabolism · 2019 · 31 citations · Full text

Medicine, Endocrinology, Pharmacology +17